OA11227A - Pharmaceutical compositions containing eletriptan hemisulphate and caffeine - Google Patents

Pharmaceutical compositions containing eletriptan hemisulphate and caffeine Download PDF

Info

Publication number
OA11227A
OA11227A OA9900271A OA9900271A OA11227A OA 11227 A OA11227 A OA 11227A OA 9900271 A OA9900271 A OA 9900271A OA 9900271 A OA9900271 A OA 9900271A OA 11227 A OA11227 A OA 11227A
Authority
OA
OAPI
Prior art keywords
composition
volume
weight
présent
éthanol
Prior art date
Application number
OA9900271A
Other languages
English (en)
Inventor
Ann Billotte
Valerie Denise Harding
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9714081.8A external-priority patent/GB9714081D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of OA11227A publication Critical patent/OA11227A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
OA9900271A 1997-07-03 1999-12-03 Pharmaceutical compositions containing eletriptan hemisulphate and caffeine OA11227A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9714081.8A GB9714081D0 (en) 1997-07-03 1997-07-03 Pharmaceutical compositions
GBGB9718270.3A GB9718270D0 (en) 1997-07-03 1997-08-28 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
OA11227A true OA11227A (en) 2003-07-18

Family

ID=26311826

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900271A OA11227A (en) 1997-07-03 1999-12-03 Pharmaceutical compositions containing eletriptan hemisulphate and caffeine

Country Status (30)

Country Link
US (1) US6166025A (de)
EP (1) EP0999841B1 (de)
JP (1) JP3350061B2 (de)
CN (1) CN1145486C (de)
AT (1) ATE206921T1 (de)
AU (1) AU724728B2 (de)
BG (1) BG103930A (de)
BR (1) BR9810658A (de)
CA (1) CA2292673C (de)
DE (1) DE69802097T2 (de)
DK (1) DK0999841T3 (de)
DZ (1) DZ2549A1 (de)
EA (1) EA002174B1 (de)
ES (1) ES2163291T3 (de)
HR (1) HRP990416B1 (de)
HU (1) HUP0004468A3 (de)
ID (1) ID24528A (de)
IL (1) IL133206A0 (de)
IS (1) IS5283A (de)
MA (1) MA26518A1 (de)
NO (1) NO312993B1 (de)
NZ (1) NZ501419A (de)
OA (1) OA11227A (de)
PL (1) PL337803A1 (de)
PT (1) PT999841E (de)
SI (1) SI0999841T1 (de)
SK (1) SK284462B6 (de)
TR (1) TR199903332T2 (de)
UY (1) UY25078A1 (de)
WO (1) WO1999001135A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
US6500834B1 (en) 1999-04-27 2002-12-31 Board Of Regents, The University Of Texas System Composition and method for treatment of cerebral ischemia
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CO5190678A1 (es) * 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia combinada para el tratamiento de la migrana
CO5190664A1 (es) * 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
IL136961A0 (en) * 1999-06-30 2001-06-14 Pfizer Prod Inc 5ht1 receptor agonists, caffeine and either a cox-2 inhibitor or nsaid for the treatment of migraine
GB9923314D0 (en) 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
WO2003020977A2 (en) * 2001-08-31 2003-03-13 The University Court Of The University Of Glasgow Nucleotide repeats assay
US7404489B1 (en) 2003-03-04 2008-07-29 Qol Medical, Llc Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
US20080286388A1 (en) * 2004-10-22 2008-11-20 Shin-Jen Shiao Pharmaceutical Composition and Non Dependence Coffee Comprising Edible Carboxylic Acid and/or Its Acid Salts and Coffeine
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
WO2007022345A2 (en) * 2005-08-17 2007-02-22 Fleming And Company, Pharmaceuticals Vitamin b12 nasal spray and method of use
US20070041905A1 (en) * 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
FR2926721B1 (fr) * 2008-01-30 2011-07-22 Philippe Perovitch Forme galenique pour l'adminsitration par voie trans-muqueuse de triptans
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
JP5776355B2 (ja) * 2010-07-16 2015-09-09 大正製薬株式会社 内服液剤
US8915245B2 (en) * 2010-10-07 2014-12-23 Vapotherm, Inc. Nebulizer systems, apparatus and methods for respiratory therapy
JP5887893B2 (ja) * 2010-12-10 2016-03-16 大正製薬株式会社 内服液剤
JP5887894B2 (ja) * 2010-12-10 2016-03-16 大正製薬株式会社 内服液剤
ES2744542T3 (es) * 2013-03-15 2020-02-25 Robert I Henkin Inhibidores de fosfodiesterasa para tratar trastornos gustativos y olfativos
EP3488889A1 (de) 2013-08-08 2019-05-29 Vapotherm, Inc. Kondensationsadapter für atemtherapien
NL1040474C2 (en) * 2013-10-31 2015-05-04 Veramed B V Nasal compositions stimulating ciliary activity.
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
JP6097787B2 (ja) * 2015-06-09 2017-03-15 パル ファーマシューティカル， インコーポレーテッド 鼻内送達用シアノコバラミン低粘度水性製剤
FR3053334B1 (fr) * 2016-06-30 2018-07-27 L'oreal Melange liquide contenant du 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one et de compose de xanthine
JP7606530B2 (ja) 2020-03-24 2024-12-25 シラノ セラピューティクス， インコーポレイテッド コロナウイルス感染症による化学感覚機能障害の治療
US12338189B2 (en) * 2023-05-24 2025-06-24 Defuse Technologies, LLC Desensitized fertilizer compositions and methods of making same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
DZ2549A1 (fr) 2003-02-08
TR199903332T2 (xx) 2000-09-21
DK0999841T3 (da) 2001-11-19
PT999841E (pt) 2002-02-28
EP0999841A1 (de) 2000-05-17
BR9810658A (pt) 2000-10-03
AU724728B2 (en) 2000-09-28
JP2000516262A (ja) 2000-12-05
CN1261279A (zh) 2000-07-26
HK1029282A1 (en) 2001-03-30
EA199901100A1 (ru) 2000-08-28
US6166025A (en) 2000-12-26
JP3350061B2 (ja) 2002-11-25
PL337803A1 (en) 2000-09-11
DE69802097T2 (de) 2002-03-14
IS5283A (is) 1999-11-30
IL133206A0 (en) 2001-03-19
ID24528A (id) 2000-07-20
EP0999841B1 (de) 2001-10-17
UY25078A1 (es) 2000-12-29
NZ501419A (en) 2000-09-29
HUP0004468A2 (hu) 2001-10-28
HUP0004468A3 (en) 2004-07-28
WO1999001135A1 (en) 1999-01-14
BG103930A (en) 2000-07-31
EA002174B1 (ru) 2002-02-28
DE69802097D1 (de) 2001-11-22
ES2163291T3 (es) 2002-01-16
HRP990416A2 (en) 2000-04-30
AU8856998A (en) 1999-01-25
NO995887L (no) 2000-03-02
SK284462B6 (sk) 2005-04-01
ATE206921T1 (de) 2001-11-15
CN1145486C (zh) 2004-04-14
MA26518A1 (fr) 2004-12-20
NO995887D0 (no) 1999-12-01
HRP990416B1 (en) 2002-04-30
CA2292673C (en) 2003-04-22
NO312993B1 (no) 2002-07-29
SI0999841T1 (de) 2001-12-31
SK182899A3 (en) 2000-09-12
CA2292673A1 (en) 1999-01-14

Similar Documents

Publication Publication Date Title
OA11227A (en) Pharmaceutical compositions containing eletriptan hemisulphate and caffeine
BE1005085A3 (fr) Medicaments.
HU199678B (en) Process for producing aerosols containing nitroglicerol
AU2020220146B2 (en) Ophthalmic compositions
US20050147564A1 (en) Inhalable formulation of a solution containing a tiotropium salt
JP2008512428A (ja) シクレソニドとＳｙｋインヒビターとの組合せ物並びにその使用方法
US6007834A (en) Nasal melatonin composition
GB2162745A (en) Nasal compositions
DK1809293T3 (en) An aerosol formulation for inhalation of beta-agonists.
AP1100A (en) Pharaceutical compositions containing eletriptan hemisulphate.
JP3498041B2 (ja) プラルモレリン含有点鼻用製剤
GB2114001A (en) Nasal pharmaceutical compositions
MXPA99011299A (en) Pharmaceutical compositions containing eletriptan hemisulphate and caffeine
CZ466099A3 (cs) Farmaceutické kompozice obsahující elektriptanhemisulfat a kofein
IE54532B1 (en) Improvements in or relating to nasal pharmaceutical compositions
TWI221769B (en) Pharmaceutical compositions containing eletriptan hemisulphate
JPH02286618A (ja) フイゾスチグミンおよびアレコリンの鼻内投与用製剤
EP0477251A1 (de) Nasale Verabreichungvon 3,3-disubstituierten Indolinen
HU211543A9 (hu) Hajtógáz nélküli nitroglicerin aeroszol helyi alkalmazás céljára Az átmeneti oltalom az 1-5. igénypontokra vonatkozik.
HK1029282B (en) Pharmaceutical compositions containing eletriptan hemisulphate and caffeine